UK – NHS rolls out ‘stop-smoking’ pill to help tens of thousands quit
Varenicline has been shown to work as well as vapes to help people stop smoking and be a more effective aid than nicotine-replacement gum...
UK – NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder
The drug can now be used as a monotherapy to treat patients in England and Wales with the three subtypes of advanced SM: aggressive...
UK – NICE recommends remote monitoring technology for heart failure patients
The National Institute for Health and Care Excellence (NICE) has announced that people with heart failure can now stay healthier remotely through advanced remote...
UK – Pfizer’s Elrexfio recommended by NICE to treat relapsed and refractory multiple myeloma
The BCMA-directed bispecific antibody will now be available for use on the NHS in England via the Cancer Drugs Fund (CDF) while more evidence...
Europe – EMA proposes updated guideline on peripheral arterial occlusive disease treatments
The European Medicines Agency (EMA) on Thursday released a draft guideline on developing drugs to treat peripheral arterial occlusive disease (PAOD) of the lower...
UK – NICE recommendation for new Alexion PNH treatment
Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan).
This first-in-class,...
UK – NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension
The National Institute for Health and Care Excellence (NICE) has issued guidance recommending Santen’s Roclanda for use in patients with primary open-angle glaucoma (POAG)...
UK – AstraZeneca’s Voydeya recommended by NICE to treat rare blood disorder PNH
The oral factor D inhibitor has been recommended for use alongside AZ’s complement component 5 (C5) inhibitors, Ultomiris (ravulizumab) or Soliris (eculizumab) to treat...
UK – Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary...
The drug can now be used in combination with ursodeoxycholic acid (UDCA) in patients with an inadequate response to UDCA, or as a monotherapy...
UK – Eli Lilly’s Alzheimer’s drug Kisunla approved by MHRA but not recommended by...
Kisunla (donanemab-azbt), administered as an intravenous infusion every four weeks, has been approved by the UK regulator to treat mild cognitive impairment and mild...
